[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sclc-limited-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sclc-limited-stage":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,77,99,125,149,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100632066","phase-1-68ga-pfd3-pet-imaging-for-the-diagnosis-and-evaluation-of-small-cell-lung-cancer-100632066",false,"NCT07508852","68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer","Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET\u002FCT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n* Adults.\n* Histologically confirmed small cell lung cancer (SCLC).\n* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.\n* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Breastfeeding.\n* Acute psychiatric disorders.\n* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).\n* Inability to complete the study procedures as anticipated.\n* Prior therapy targeting DLL3.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).",[27,28,29,30,31],"SCLC","SCLC, Extensive Stage","SCLC, Limited Stage","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )",[27,33,34,35,36,37,38,39,40],"small cell lung cancer","PET\u002FCT","PET","DLL3","Delta-like ligand 3","imaging","diagnosis","evaluation","RECRUITING","2026-06-16",{"date":44,"type":45},"2026-06-18","ACTUAL",{"date":47,"type":45},"2025-10-22",{"date":49,"type":20},"2027-12-31",{"name":51,"class":52},"Peking University First Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":53},"100635984","phase-2-a-multicenter-randomized-cohort-prospective-clinical-study-of-adebrelimab-consolidation-therapy-for-limited-stage-small-cell-lung-cancer-ls-sclc-without-progression-after-concurrent-chemoradiotherapy-100635984","NCT07559786","A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy","Inclusion Criteria:\n\n1.Age ≥ 18 and ≤ 75 years, regardless of gender. 2.Histopathologically confirmed, untreated limited-stage small cell lung cancer (LS-SCLC) (stage I-III per AJCC 8th edition, with all lesions encompassed in a tolerable radiation plan).\n\n3.Clinically staged T1-2N0, operable LS-SCLC patients who are ineligible for surgery or refuse surgery.\n\n4.ECOG performance status 0-1. 5.Expected survival ≥ 3 months. 6.At least one measurable lesion per RECIST 1.1. 7.Pulmonary function: FEV1 \\> 70% of predicted value. 8.Adequate hematologic and end-organ function, with laboratory results obtained within 7 days before first study treatment:\n\n1. Hematology: Absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL without G-CSF support within 14 days before first treatment; lymphocyte count (LC) ≥ 0.5×10⁹\u002FL; platelet count (PLT) ≥ 90×10⁹\u002FL without transfusion, G-CSF, or other hematopoietic stimulants within 14 days before first treatment.\n2. Hepatic function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN; total bilirubin (TBIL) ≤ 1.5 × ULN (≤3.0 mg\u002FdL for patients with confirmed Gilbert syndrome).\n3. Renal function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 50 mL\u002Fmin (calculated by Cockcroft-Gault, CKD-EPI, or MDRD equation); urine protein \\\u003C 2+ (if urine protein ≥ 2+, 24-hour urine protein must be \\\u003C 1 g for eligibility).\n4. Coagulation: International normalized ratio (INR) ≤ 1.5; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n5. Echocardiography: Left ventricular ejection fraction (LVEF) ≥ 50%. 9.Sexually active subjects of reproductive potential (non-sterilized) must agree to use at least one medically accepted contraceptive method during study treatment and for 3 months after treatment completion. For females of reproductive potential: serum pregnancy test (HCG) must be negative within 7 days before first dosing.\n\n10.Subjects are voluntarily enrolled, provide written informed consent, have good compliance, and agree to follow-up.\n\nExclusion Criteria:\n\n1. Histologically confirmed combined small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC).\n2. Prior systemic anti-tumor therapy or immune checkpoint inhibitor therapy for SCLC.\n3. Extensive-stage SCLC.\n4. Presence of malignant pleural effusion. If aspiratable pleural effusion is present during screening, at least one thoracentesis must be performed to confirm the presence or absence of malignant cells.\n5. Subjects with known or suspected interstitial lung disease (ILD); other moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity and severely impair respiratory function, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia\u002Fbronchiolitis obliterans, etc.\n6. History of active, known or suspected autoimmune disease, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.\n\n   (Exceptions: Type 1 diabetes mellitus (glycemic control with insulin); residual hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy; conditions not expected to relapse in the absence of external trigger.\n\n   Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo only (excluding psoriatic arthritis) may be enrolled if: rash involves \\\u003C10% of body surface area; disease is well controlled at baseline with only low-potency topical steroids; and no acute exacerbation in the past 12 months (no PUVA, methotrexate, retinoids, biologics, oral calcineurin inhibitors, high-potency or oral steroids).)\n7. Concomitant malignancy diagnosed ≤3 years before first study treatment, except adequately treated papillary thyroid carcinoma, cervical carcinoma in situ, basal or squamous cell skin cancer, locally controlled prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery (hormonal therapy for non-metastatic prostate or breast cancer is allowed).\n8. History of clinically significant cardiovascular disease, including but not limited to:\n\n   Congestive heart failure (NYHA class \\>2); Unstable angina; Myocardial infarction within 3 months before signing ICF; Any severe supraventricular or ventricular arrhythmia requiring treatment or intervention.\n9. Severe infection within 4 weeks before first treatment, including but not limited to bacteremia requiring hospitalization, severe pneumonia, etc.; active infection of CTCAE grade ≥2 requiring systemic antibiotics within 2 weeks before first treatment.\n10. Active tuberculosis within 1 year before enrollment by history or CT scan, or history of active tuberculosis \\>1 year ago without standard treatment.\n11. History of immunodeficiency, including positive HIV serology.\n12. Active hepatitis B or hepatitis C.(HBsAg-positive or HBcAb-positive subjects may be enrolled if HBV DNA \\\u003C upper limit of normal (ULN) of the local laboratory (if no ULN, HBV DNA \\\u003C1000 copies\u002FmL or 500 IU\u002FmL); HCV Ab-positive subjects may be enrolled if HCV RNA \\\u003C ULN of the local laboratory (if no ULN, HCV RNA \\\u003C500 IU\u002FmL).)\n13. Receipt of systemic immunosuppressive therapy within 14 days before first treatment, including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents.\n\n(1)Patients receiving short-term systemic immunosuppression (e.g., corticosteroids for management\u002Fprophylaxis of nausea, vomiting, or hypersensitivity) may be enrolled at the investigator's discretion; a washout period before randomization may be required.\n\n(2)Allowed: inhaled corticosteroids for COPD; mineralocorticoids (e.g., fludrocortisone) for orthostatic hypotension; low-dose corticosteroid replacement (≤10 mg\u002Fday prednisone or equivalent) for adrenal insufficiency.\n\n14.Major surgery within 28 days before first treatment (except diagnostic surgery), or expected major surgery during the study (except diagnostic surgery).\n\n15.Administration of live attenuated vaccine within 28 days before first treatment, or anticipated need during the study (live attenuated influenza vaccine is prohibited within 28 days before first treatment, during treatment, and for 5 months after the last dose of adebrelimab).\n\n16.Prior allogeneic bone marrow transplant or solid organ transplant. 17.History of severe hypersensitivity to monoclonal antibody\u002Ffusion protein drugs.\n\n18.Known psychiatric disorder, alcoholism, drug abuse or substance abuse. 19.Any other condition that, in the investigator's judgment, may prematurely terminate the study, e.g., poor protocol compliance, other severe diseases requiring concurrent treatment, significant laboratory abnormalities, or family\u002Fsocial factors affecting subject safety or data\u002Fsample collection.","75 Years",{"count":62,"type":20},200,[24],"This study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer. This study plans to enroll patients with untreated limited-stage small cell lung cancer who meet the inclusion criteria. The eligible patients will be randomly divided 1:1 into two groups to receive treatment regimens for residual lymph nodes and involved irradiated areas. That is, carboplatin AUC 5, D1 + etoposide 100 mg\u002Fm…\\^2 on days 1, 2, and 3 + thoracic radiotherapy (residual lymph nodes or involved irradiated areas), with each 3-week cycle.After 4 cycles of concurrent chemoradiotherapy, the non-progressing subjects will continue to receive adebrelimab (1200 mg, IV, Q3W) maintenance therapy.",[29],"NOT_YET_RECRUITING","2026-04-27",{"date":69,"type":45},"2026-04-30",{"date":71,"type":20},"2026-04-01",{"date":73,"type":20},"2029-04-01",{"name":75,"class":76},"Henan Cancer Hospital","OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100616715","durvalumab-as-consolidation-therapy-in-patients-with-ls-sclc-following-scrt-100616715","NCT07309211","Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT","A Multi-centre, Retrospective Study Assessing Durvalumab as Consolidation Treatment for Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) Following by Sequential Chemoradiotherapy (sCRT)","Inclusion Criteria:\n\n1. Aged ≥18 at initial diagnosis;\n2. Histological or cytological evidence of LS-SCLC (Stage I-III); Stage I-II must be medically inoperable;\n3. Received chemotherapy sequential with radiotherapy as first-line treatment and no progression, followed by receiving Durvalumab at least 1 dose as consolidation treatment until progression, unacceptable toxicity or for a maximum of 24 months;\n4. Start Durvalumab treatment within 3 months after sCRT;\n5. Permitted PCI;\n6. WHO PS 0-2 before sCRT.\n\nExclusion Criteria:\n\n1. ES-SCLC or mixed SCLC and NSCLC histology;\n2. Active or prior documented autoimmune or inflammatory disorders or uncontrolled intercurrent illness;\n3. Any unresolved toxicity (CTCAE Grade ≥ 2) from prior chemoradiotherapy; 4. Received concurrent chemoradiotherapy for LS-SCLC.",{"count":85,"type":20},25,"OBSERVATIONAL","This is a retrospective, multi-centre, single arm study to assess the safety and efficacy of receiving Durvalumab in patients with Small Cell Lung Cancer Limited Stage (LS-SCLC) who have not progressed following sequential chemoradiotherapy (sCRT) in a real-world setting. The study will enroll 25 patients. The primary endpoint of the study is the incidence of Grade 3 or 4 adverse events (AEs) within 6 months of starting Durvalumab (graded by CTCAE v.5.0). The secondary endpoints of the study include real-world progression-free survival (rwPFS, the time from the start of Durvalumab treatment to disease progression or death for any reason, which occurs first), objective response rate (ORR), duration of response (DoR) and disease control rate (DCR).\n\nsCRT is more common in Mid-Eastern Chinese clinical practice. sCRT is also recommended in guideline of Chinese Society of Clinical Oncology (CSCO) Small-cell lung cancer. However, patients treated with sCRT were not included in the ADRIATIC study. So there is lack of data on safety and efficacy of Durvalumab post sCRT. Supplement real-world evidence (RWE) clinical data of sCRT in Chinese patients is needed to enhance the status of Durvalumab as a consolidation therapy for LS-SCLC.\n\nThe study will retrospectively collect cases of eligible LS-SCLC patients who received sCRT and have not progressed followed by receiving Durvalumab as consolidation therapy.",[29],"2025-12-29",{"date":91,"type":45},"2025-12-30",{"date":93,"type":45},"2025-07-08",{"date":95,"type":20},"2026-12",{"name":97,"class":52},"The First Affiliated Hospital with Nanjing Medical University",4,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100593613","phase-3-omitting-ctv-for-primary-tumor-in-ls-sclc-100593613","NCT07008716","Omitting CTV for Primary Tumor in LS-SCLC","Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;\n2. Aged 18-75 years, KPS score ≥ 80, ≤ 10% weight loss within the past 6 months;\n3. Have measurable lesions per RECIST 1.1 criteria;\n4. Have no disease progression after 2-4 cycles of etoposide\u002Fcarboplatin or etoposide\u002Fcisplatin;\n5. Lung function test: FEV1 ≥ 1 L (Optional);\n6. Complete blood count: neutrophil count ≥ 1.5 x 10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, platelet count ≥ 100 x 10\\^9\u002FL;\n7. Renal function: serum creatinine ≤ 1.5 x upper limit of normal (ULN);\n8. Liver function: AST and ALT ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN;\n9. Fully understand the study, able to complete treatment and follow-up, and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Other malignant tumors (prior or concurrent), except those that have been curatively treated with disease-free survival ≥ 5 years, such as non-melanoma skin cancer, cervical carcinoma in situ, or early-stage papillary thyroid cancer;\n2. Uncontrolled heart disease or myocardial infarction within the past 6 months;\n3. Patients with a history of mental illness;\n4. Pregnant and lactating patients;\n5. Poorly controlled diabetes and hypertension;\n6. Interstitial pneumonia or active pulmonary fibrosis;\n7. Active infection;\n8. Other conditions unsuitable for enrollment (per investigator judgment).",{"count":107,"type":20},852,[109],"PHASE3","This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk and the side effects.",[29,112,113,114],"Radiation Exposure","Radiotherapy Side Effect","Progression","2025-05-29",{"date":117,"type":45},"2025-06-06",{"date":119,"type":20},"2025-06-03",{"date":121,"type":20},"2032-12-31",{"name":123,"class":52},"Sun Yat-sen University",2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":86,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100412731","lung-cancer-registry-100412731","NCT04654364","Lung Cancer Registry","Inclusion Criteria:\n\n* stage III A-C and IV A-B NSCLC\n* limited disease (LD) and extensive disease (ED) SCLC)\n* patients ≥ 18 years\n\nExclusion Criteria:\n\n\\- Due to the non-interventional design of the registry there are no specific exclusion criteria.",{"count":132,"type":20},500,"5 Years","Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. Therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women.\n\nThis malignant disease can be divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. Despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. For these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. Until recently, little progress has been made in the treatment of SCLC in last decades. Recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced SCLC has been reported.\n\nDespite the progress in the treatment of NSCLC, the performance of predictive biomarkers is weak. Therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.",[136,137,138,28,29],"Lung Cancer","NSCLC Stage IV","NSCLC, Stage III","2025-04-09",{"date":141,"type":45},"2025-04-10",{"date":143,"type":45},"2020-08-18",{"date":145,"type":20},"2030-08",{"name":147,"class":52},"Arbeitsgemeinschaft medikamentoese Tumortherapie",3,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":53},"100586148","phase-2-study-of-serplulimab-plus-chemotherapy-as-neoadjuvant-therapy-for-limited-stage-small-cell-lung-cancer-ls-sclc-100586148","NCT06911606","Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)","A Prospective Phase II Clinical Study of Serplulimab Combined With Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) Followed by Surgery or Radiotherapy","Inclusion Criteria:\n\n1. Voluntarily participate in clinical research and sign written informed consent\n2. Male or female patients aged 18-75 years old (including the critical value)\n3. Histologically or cytologically confirmed SCLC\n4. Clinically diagnosed as IIB-IIIB ( N2) stage (AJCC 8th edition cancer staging)\n5. Patients who have not received systemic anti-tumor treatment or chest radiotherapy in the past\n6. By Surgeons evaluate patients who have no contraindications to surgery\n7. According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), there is at least one radiologically measurable lesion\n8. ECOG score 0-1\n9. Expected survival time \\> 6 months\n10. Hepatitis B surface antigen (HBsAg) (-) and hepatitis B core antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), the hepatitis B virus deoxyribonucleic acid (HBV-DNA) must be \\\u003C2500 copies\u002FmL or 500 IU\u002FmL before inclusion. Subjects who are HCV antibody (-) or HCV-RNA negative can be enrolled if HCV-RNA is positive, the subject must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ Only 3×ULN can join the group. Subjects who are co-infected with hepatitis B and hepatitis C need to be excluded (positive HBsAg or HBcAb test, and positive HCV antibody test)\n11. Laboratory tests within 7 days before the first use of the study drug confirm sufficient organ and bone marrow function, No serious hematopoietic abnormalities, cardiac, liver, renal dysfunction or immune deficiency (no blood transfusion, albumin, recombinant human thrombopoietin or colony-stimulating factor (CSF) treatment within 14 days before the first medication in this study)\n12. Female patients must meet one of the following conditions: a. Menopause (defined as the absence of menstruation for at least 1 year without other confirmed reasons other than menopause), or b. Have undergone surgical sterilization (removal of ovaries and\u002For uterus) , or c. Have childbearing potential, but must meet the following requirements: the serum\u002Furine pregnancy test within 7 days before enrollment must be negative, and agree to use contraceptive measures with an annual failure rate of \\\u003C1% or maintain abstinence (avoiding heterosexual intercourse) (from signing ICF to at least 6 months after the last dose of study drug) (contraceptive methods with annual failure rates \\\u003C1% include bilateral fallopian tube ligation, male sterilization, correct use of hormonal contraceptives that inhibit ovulation, and hormone-releasing intrauterine contraception devices and copper-containing IUDs or condoms), and you must not breastfeed.\n13. Male patients must meet the following requirements: Agree to abstain from sex (avoid heterosexual intercourse) or take contraceptive measures, as follows: When the partner is a female of childbearing age or the partner is pregnant, the male patient must agree to abstain from sexual intercourse (avoiding heterosexual intercourse) or take contraceptive measures for at least 6 months during the study treatment period and after the last dose of the study drug. Maintain abstinence or use condoms during the first trimester to prevent embryonic drug exposure. Periodic abstinence (for example, calendar days, ovulation period, basal body temperature or post-ovulation contraceptive method) and in vitro ejaculation are unqualified contraceptive methods\n14. The end of previous non-systemic anti-tumor treatment must be ≥ 2 weeks from the start of medication, and according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0, treatment-related AEs reverted to grade ≤1 (except grade 2 alopecia).\n\nExclusion Criteria:\n\n1. Mixed SCLC confirmed by histology or cytology\n2. Previously received systemic anti-tumor treatment for small cell lung cancer, including but not limited to chemotherapy, immunotherapy, and radiotherapy\n3. Other active malignant tumors within 5 years or at the same time. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, and carcinoma in situ of the breast, can be enrolled\n4. Those who are planning to undergo or have received organs in the past or bone marrow transplant patients\n5. Pleural effusion, pericardial effusion or ascites requiring clinical intervention\n6. Myocardial infarction or poorly controlled arrhythmia (including men with QTc interval) within 6 months before the first administration of the study drug ≥450 ms, women ≥470 ms) (QTc interval is calculated by Fridericia's formula)\n7. The subject has uncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium or calcium \\> 12 mg\u002FdL or Corrected serum calcium \\> ULN)\n8. The patient has grade ≥ 2 CTCAE peripheral neuropathy\n9. Human immunodeficiency virus (HIV) infection, HIV antibody test results are positive\n10. Suffering from active pulmonary tuberculosis\n11. Past and There are currently subjects with interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired lung function, etc. who are judged by the researcher to be likely to interfere with the detection and treatment of suspected drug-related pulmonary toxicity\n12. Hepatitis B (HBsAg or HBcAb test is positive, and HBV-DNA test is positive), Hepatitis C (HCV antibody test is positive, and HCV-RNA test is positive). Subjects with co-infection of hepatitis B and hepatitis C (positive HBsAg or HBcAb test, and positive HCV antibody test). Note: Hepatitis B patients who have been stabilized by antiviral treatment (HBV-DNA ≤ 2500 copies\u002FmL or 500IU\u002FmL) can be enrolled\n13. Subjects have known active or suspected autoimmune diseases. Subjects who are in stable condition and do not require systemic immunosuppressant treatment are allowed to enroll\n14. Those who have received live vaccine treatment within 28 days before the first dose. However, inactivated viral vaccines are allowed to treat seasonal influenza, but intranasal live attenuated influenza vaccines are not allowed\n15. Systemic corticosteroids (\\> 10 mg\u002F subjects treated with prednisone effective doses) or other immunosuppressive drugs. However, the following conditions are allowed: in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at a dose of ≤ 10 mg\u002Fday prednisone effective dose\n16. Any active infection requiring systemic anti-infectious therapy within 14 days before study drug administration, or the subject has a positive RT-PCR test for SARS-CoV-2 infection at enrollment. Subjects with a history of COVID-19 infection must have a negative RT-PCR test before the first administration of the study drug\n17. Have undergone major surgery within 28 days before the first administration of the study drug. The definition of major surgery in this study: at least 3 weeks of recovery time are required after surgery before the surgery can be treated in this study\n18. The subject has previously received other antibodies\u002Fdrugs targeting immune checkpoints, such as PD-1, PD -L1, CTLA-4 and other treatments\n19. Are participating in other interventional clinical studies, or plan to start treatment in this study less than 28 days from the end of treatment in a previous interventional clinical study\n20. Known to have a risk for any monoclonal antibody History of severe allergies\n21. Known allergic reaction to carboplatin\u002Fcisplatin or etoposide components\n22. Pregnant or lactating women\n23. Subjects known to have a history of psychotropic drug abuse or drug use\n24. According to the researcher's judgment, the subject has other factors that may cause the study to be terminated early.",{"count":157,"type":20},45,[24],"This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC",[29],[162],"II-IIIB (N2) LS-SCLC","2025-03-28",{"date":165,"type":45},"2025-04-04",{"date":167,"type":45},"2024-05-22",{"date":169,"type":20},"2026-06-30",{"name":171,"class":52},"Guangdong Provincial People's Hospital",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":194,"locationsCount":53},"100544637","phase-2-durvalumab-combined-with-chemoradiotherapy-for-limited-stage-small-cell-lung-cancer-camel-01-100544637","NCT06371482","Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)","Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Voluntary participation and written signed informed consent;\n* Age 18-75 years old, gender is not limited;\n* Histologically or cytologically confirmed limited-stage small cell lung cancer (2009 AJCC\u002FUICC\u002FIASLC lung cancer TNM staging criteria, limited-stage SCLC is any T stage, any N stage, and M0), and patients with suspected brain or bone metastasis at the time of screening should undergo brain MRI or ECT before study enrollment;\n* There are immunohistochemical results;\n* Chemotherapy must include either cisplatin or carboplatin, in combination with etoposide;\n* Physical status score ECOG 0-1;\n* Weight \\> 40 kg;\n* Expected survival ≥ 6 months;\n* According to RECIST 1.1 guidelines, at least one lesion (not previously receiving radiotherapy) with a maximum diameter ≥ 10 mm as accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline (except lymph nodes, whose short axis must be ≥ 15 mm); And the lesion is suitable for repeated accurate measurement.;\n* No previous immunotherapy;\n* no serious abnormalities of haematopoietic, cardiac, pulmonary, hepatic; and renal functions and immunodeficiency (Haematology: white blood cells ≥3.5×109\u002FL; neutrophils ≥1.5×109\u002FL; haemoglobin ≥90g\u002FL; platelets\n\n  ≥100×109\u002FL. Liver and kidney function: total bilirubin ≤1.5 times the upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) ≤2.5 times the upper limit of normal; creatinine ≤1.5 times the upper limit of normal; albumin ≥30 g\u002FL. Coagulation: International Normalised Ratio (INR) or Prothrombin Time (PT) or Activated Partial Thromboplastin Time (APTT)\n\n  ≤ 1.5 times ULN; if the subject is receiving anticoagulation therapy, PT or INR is acceptable as long as the PT or INR is within the range of the anticoagulant drug formulation. Echocardiographic assessment: left ventricular ejection fraction (LVEF) ≥ low limit of normal (50%). Pulmonary function FEV1 ≥70% of % of predicted value and DLCO ≥60% of % of predicted value).\n* The female patient has evidence of postmenopausal status, or the urine or serum pregnancy test results of the premenopausal woman are negative. Women who stop menstruating for 12 months without other medical reasons are considered menopausal.\n\nExclusion Criteria:\n\n* Distant organ metastases (excluding supraclavicular lymph nodes) as determined by CT evaluation during screening and prior imaging;\n* have received prior radiotherapy to the chest;\n* have medical contraindications to etoposide - platinum (carboplatin or cisplatin) based chemotherapy;\n* having any active autoimmune disease or a history of autoimmune disease (e.g. interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which can be included if hormone replacement therapy is effective), etc.), and a history of immunosuppressive drug use within 28 days, with the exception of the use of hormones for the purpose of dealing with toxicity from radiotherapy;\n* Previously received or are receiving other PD-1 antibody therapy or other immunotherapy targeting PD-1\u002FPD-L1, or are currently participating in other interventional clinical studies for treatment;\n* Have received other anti-tumour therapy (including herbal therapy with anti-tumour effect) within 4 weeks prior to the first dose of the study; have received long-term systemic immunotherapy or hormone therapy (except physiological replacement therapy, e.g., oral thyroxine for hypothyroidism) within 4 weeks prior to the first dose of the study; and have been treated with other experimental drugs or interventional clinical studies within 4 weeks prior to the first dose of the study;\n* Patients with uncontrolled clinical cardiac symptoms or disease such as\n\n  (1) NYHA class II or higher heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, and (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;\n* with congenital or acquired immune function defects (e.g., HIV-infected patients), active hepatitis B (HBV-DNA ≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody-positive with HCV-RNA above the lower limit of detection of the analytical method), or active tuberculosis;\n* Have an active infection or unexplained fever \\>38.5°C within 2 weeks prior to screening (at the investigator's discretion, subjects may be enrolled for fever arising from tumours);\n* In the judgement of the investigator, the subject has other factors that may cause him\u002Fher to be forced to terminate the study in the middle of the study, e.g., suffering from other serious illnesses (including psychiatric illnesses) that require comorbid treatment, family or social factors that may affect the safety of the subject or the collection of trial data.",{"count":180,"type":20},58,[24],"This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.",[29],[29,185,186,187],"immunotherapy","chemoradiotherapy","Durvalumab","2024-06-13",{"date":190,"type":45},"2024-06-17",{"date":192,"type":45},"2023-06-01",{"date":49,"type":20},{"name":195,"class":52},"Hebei Medical University Fourth Hospital"]